217 related articles for article (PubMed ID: 20675596)
1. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
Fang Y; Larsson L; Mattsson J; Lycke N; Xiang Z
J Immunol; 2010 Sep; 185(5):2935-41. PubMed ID: 20675596
[TBL] [Abstract][Full Text] [Related]
2. The immune complex CTA1-DD/IgG adjuvant specifically targets connective tissue mast cells through FcγRIIIA and augments anti-HPV immunity after nasal immunization.
Fang Y; Zhang T; Lidell L; Xu X; Lycke N; Xiang Z
Mucosal Immunol; 2013 Nov; 6(6):1168-78. PubMed ID: 23571505
[TBL] [Abstract][Full Text] [Related]
3. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
Agren LC; Ekman L; Löwenadler B; Lycke NY
J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
[TBL] [Abstract][Full Text] [Related]
5. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
Lycke N
Curr Opin Mol Ther; 2001 Feb; 3(1):37-44. PubMed ID: 11249730
[TBL] [Abstract][Full Text] [Related]
6. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
[TBL] [Abstract][Full Text] [Related]
7. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
8. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.
Bemark M; Bergqvist P; Stensson A; Holmberg A; Mattsson J; Lycke NY
J Immunol; 2011 Feb; 186(3):1399-410. PubMed ID: 21199899
[TBL] [Abstract][Full Text] [Related]
9. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
10. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
[TBL] [Abstract][Full Text] [Related]
11. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.
Mattsson J; Yrlid U; Stensson A; Schön K; Karlsson MC; Ravetch JV; Lycke NY
J Immunol; 2011 Oct; 187(7):3641-52. PubMed ID: 21880985
[TBL] [Abstract][Full Text] [Related]
12. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
[TBL] [Abstract][Full Text] [Related]
13. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
14. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
Lycke N; Schön K
Vaccine; 2001 Mar; 19(17-19):2542-8. PubMed ID: 11257390
[TBL] [Abstract][Full Text] [Related]
15. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
Agren L; Sverremark E; Ekman L; Schön K; Löwenadler B; Fernandez C; Lycke N
J Immunol; 2000 Jun; 164(12):6276-86. PubMed ID: 10843681
[TBL] [Abstract][Full Text] [Related]
16. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
Sundling C; Schön K; Mörner A; Forsell MNE; Wyatt RT; Thorstensson R; Hedestam GBK; Lycke NY
J Gen Virol; 2008 Dec; 89(Pt 12):2954-2964. PubMed ID: 19008380
[TBL] [Abstract][Full Text] [Related]
17. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
18. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
Agren L; Löwenadler B; Lycke N
Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
[TBL] [Abstract][Full Text] [Related]
19. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
